Loading

Investor Relations

Corporate Profile

We are a late stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with various conditions. We believe that serlopitant, a highly selective small molecule inhibitor of the neurokinin 1 receptor, or NK1R, given as a once daily, oral tablet, has the potential to significantly alleviate pruritus associated with various conditions.

Copyright West LLC. Minimum 15 minutes delayed.

Events

Menlo Therapeutics Announces Results from a Phase 2 Clinical Trial of Serlopitant for the Treatment of Refractory Chronic Cough

Serlopitant fails to demonstrate efficacy relative to placebo on primary and secondary endpoints REDWOOD CITY, Calif. , Oct. 08, 2018 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO) a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of

Menlo Therapeutics Begins European Prurigo Nodularis Phase 3 Trial and Presents Additional Data from PN Phase 2 Trial at EADV

~Additional Exploratory Analyses of Phase 2 Clinical Trial of Serlopitant in Prurigo Nodularis Presented at the European Academy of Dermatology and Venereology Congress~ REDWOOD CITY, Calif. , Sept. 17, 2018 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc.

Menlo Therapeutics Reports Second Quarter 2018 Financial Results and Provides Business Update

~ Phase 2 Data in Refractory Chronic Cough Expected in October 2018 ~ ~ Phase 2 Data in Psoriasis Expected December 2018 or January 2019 ~ ~ New Phase 2 Study in Chronic Pruritus of Unknown Origin Expected to Start in Q4 2018 ~ REDWOOD CITY, Calif. , Aug.